Researchers identify potential new approaches for early detection and treatment of atherosclerosis

Blockage of arterial blood vessels caused by atherosclerosis is largely responsible for heart attacks and strokes, which are the most common causes of death worldwide.

GH Research’s Psychedelic Drug Candidate For Depression Meets FDA: Clinical Program On Hold

After the usual 30-day review period, the Food and Drug Administration (FDA) placed GH Research’s GHRS Investigational New Drug (IND) application for a Phase 1 clinical trial of

October 3, 2023

Canadian Cannabis Sales Rebound In July

Statistics Canada released July retail sales for the country, with cannabis sales increasing from the June levels, up 1.6% to C$440.7 million. On a per-day basis, sales

September 20, 2024

New Schizophrenia Treatments Are Coming: Don’t Panic

At the recent Psych Congress 2023, a session titled “State of the Science: Focus on Schizophrenia” was presented by Peter J. Weiden, MD, a clinical

September 27, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.